Literature DB >> 25566684

Maintenance chemotherapy in the management of epithelial ovarian cancer.

Maurie Markman1.   

Abstract

The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient's quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25566684     DOI： 10.1007/s10555-014-9537-x

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN： 0167-7659            Impact factor:   9.264


  8 in total

1.  Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

Authors:  Jonathan A Ledermann; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew R Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; Terri Cameron; Lara Maloney; Sandra Goble; Robert L Coleman
Journal:  Lancet Oncol       Date:  2020-05       Impact factor: 41.316

Review 2.  Ovarian cancer.

Authors:  Ursula A Matulonis; Anil K Sood; Lesley Fallowfield; Brooke E Howitt; Jalid Sehouli; Beth Y Karlan
Journal:  Nat Rev Dis Primers       Date:  2016-08-25       Impact factor: 52.329

3.  Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.

Authors:  Ana Oaknin; Amit M Oza; Domenica Lorusso; Carol Aghajanian; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Andrew R Clamp; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; Terri Cameron; Lara Maloney; Sandra Goble; Jonathan A Ledermann; Robert L Coleman
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

4.  Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.

Authors:  Andrew R Clamp; Domenica Lorusso; Amit M Oza; Carol Aghajanian; Ana Oaknin; Andrew Dean; Nicoletta Colombo; Johanne I Weberpals; Giovanni Scambia; Alexandra Leary; Robert W Holloway; Margarita Amenedo Gancedo; Peter C Fong; Jeffrey C Goh; David M O'Malley; Deborah K Armstrong; Susana Banerjee; Jesus García-Donas; Elizabeth M Swisher; Terri Cameron; Sandra Goble; Robert L Coleman; Jonathan A Ledermann
Journal:  Int J Gynecol Cancer       Date:  2021-06-08       Impact factor: 4.661

5.  Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells.

Authors:  Dan Zi; Zhi-Wei Zhou; Ying-Jie Yang; Lin Huang; Zun-Lun Zhou; Shu-Ming He; Zhi-Xu He; Shu-Feng Zhou
Journal:  Int J Mol Sci       Date:  2015-11-13       Impact factor: 5.923

6.  Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy.

Authors:  Hiroaki Nagano; Yasunari Tachibana; Megumi Kawakami; Mariko Ueno; Yoshihiro Morita; Mitsue Muraoka; Koichiro Takagi
Journal:  Case Rep Oncol       Date:  2016-03-23

Review 7.  Frontline Maintenance Treatment for Ovarian Cancer.

Authors:  Osnat Elyashiv; Yien Ning Sophia Wong; Jonathan A Ledermann
Journal:  Curr Oncol Rep       Date:  2021-06-14       Impact factor: 5.075

Review 8.  Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Authors:  Thomas J Herzog; Bradley J Monk
Journal:  Gynecol Oncol Res Pract       Date:  2017-09-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.